Objective Erlotinib (Trade Name:Tarceva) is a new targeted drug for the treatment of non-small cell lung cancer (NSCLC) that has a wide clinical application in recent years, but commonly carries many side effects, among which the most common and unbearable one is rash. The aim of this study is to observe the changes of epidermis, pathology, immunohistochemistry and other aspects before and after the application of Tarceva in mice and try to copy the rash animal models caused by Tarceva and thus to provide models for the clinical topical medications of rash. Methods 20BALB/c female mice were randomly divided into four groups.The experimental group(Ⅱ、Ⅲ、Ⅳ group) was given 100 mg/kg dosage with the concentration of 10 g/L erlotinib solution by gavage, and the control group (I group)with an equal volume of deionized water by gavage once daily. The hairs from the head,neck and back of each mouse were removed 24 hours prior to the administration,and at the end of the experiment, clipping the skin in the neck, back and waist,then observed differences between the experimental group and the control group in mice skin, biopsy, immunohistochemistry and the like. Results (1) There were statistically significance (P<0.01 or P<0.05) in the four groups of mice in five aspects as hair regrowth days, days of the complete regrowth of hair, desquamation time, the time of appearance of rash and the number of pore expansion;(2) Ki67:There were no statistically significant differences among the four groups(P>0.05).Conclusions (1) This experiment confirms many researchers' point of view that "the rash induced by EGFRIs is an inflammatory response"(2) A mouse model of rash induced by FGFRIs is successfully established,and this is a reliable,practical and reproducible model which applies to a large number of establishment of "EGFRIs drug-induced rash in animal models",and can be popularized for clinical,experimental and institutional uses.